KA Kineta Bio: Forward Price-to-Revenue Multiple

Corporate emblem and logo of Kineta (KA)

Kineta, Inc. (KA) is creating a closed scientific loop by tying pharma behemoths to monoclonal antibody research. This price-to-sales chart from GURU.Markets shows that the latest reading is 1.20. While the company develops methods for the immune system to detect hidden tumors, liquidity shortages and workforce reductions have created critical risks that necessitate strict control over patent sales.

KA (kinetabio.com) Price to Expected Revenue Ratio history from 04/28/2023 to 08/10/2024

KA (Kineta Corp): analytical breakdowns and indicator data

- market price and analyst price targets:
Price Chart Kineta|KA - Average Forecast Price
- company stock capitalization data:
Market Valuation Kineta Corp|KA - Full Takeover Company Value
- business book valuation details:
Accounting Value per Share Kineta|KA - Total Net Assets|Market Capitalization to Book Value Ratio kinetabio.com|KA - Aggregate Asset Value
- debt and liquidity details:
Total Debt to Capital Kineta, Inc.|KA - Long-Term Liabilities to Capital|Short-Term Debt to Equity Kineta, Inc.|KA - Aggregate Debt Obligations|Debts to Book Capitalization Kineta Corp|KA - Company Long-Term Debts|Company Short-Term Debt Kineta|Quick Liquidity Indicator kinetabio.com
- net income and valuation multiples indicators:
KA - Company Net Income|Expected Profit Kineta, Inc.|KA - P/E Multiple|Forward P/E Multiple Kineta Bio|KA - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Kineta Corp|KA - Operating profit before amortization|Net earnings per share (EPS TTM) Kineta|KA - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months kinetabio.com|KA - Net earnings per one share growth for the current year|Earnings growth forecast for next year Kineta, Inc.
- issuer revenue and sales details:
KA - Revenue and Sales Volume|Company Future Sales Volume Kineta|KA - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple Kineta Corp
Summary company analysis:Kineta KA
Product sample of Kineta, Inc.

For Kineta, Inc. (KA), which possesses pricing power due to the uniqueness of the KVA12.1 antibody in immuno-oncology, this metric reflects the market valuation of future revenues relative to current capitalization. By analyzing the forward P/S trend, an investor determines the market's level of confidence in the drug's sales potential under inelastic demand, where sharp amplitude fluctuations signal a reassessment of the business's fundamental ability to monetize its technological advantages.

Competitors of Kineta, Inc.

Price-to-Projected Revenue Ratio ImmunityBio IBRX|Immunocore Holdings (IMCR) - Market Cap to Future Revenue Ratio|JANX: Forward Price-to-Revenue Multiple|Projected Price to Revenue Arcus Corp (RCUS)|ZYME (Zymeworks Inc.) - Forward Price-to-Revenue Multiple|TNGX: Price to Expected Revenue Ratio|IOVA (Iovance Biotherapeutics, Inc.) - Forward P/S Multiple|IMTX: Forward Price to Sales|Forward P/S Multiple XNCR|CMPX - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Replimune Group, Inc. REPL|Forward Price to Sales LYEL|Innate Pharma - Forward P/S Multiple|PYXS - Forward P/S Multiple|cgen.com (CGEN) - Price-to-Projected Revenue Ratio|Future Price to Revenue IOBT (IO Biotech Inc.)|Forward Price-to-Revenue Multiple STRO|Market Cap to Future Revenue Ratio minktherapeutics.com INKT|Price-to-Projected Revenue Ratio Werewolf Therapeutics (HOWL)|Forward P/S Multiple immixbio.com (IMMX)|Forward P/S Multiple ALXO (ALX Oncology Holdings)|Market Cap to Expected Sales Ratio cuebiopharma.com (CUE)|PDSB - Price-to-Projected Revenue Ratio|SONN (Sonnet BioTherapeutics) - Market Cap to Projected Revenue|MAIA: Forward P/S Multiple|Market Cap to Future Revenue Ratio Liminatus Pharma Inc. (LIMN)|Forward Price-to-Revenue Multiple LVTX|NXTC (NextCure Corporation) - Price to Expected Revenue Ratio|Forward P/S Multiple LPTX|Forward P/S Multiple intensitytherapeutics.com (INTS)|Sensei Biotherapeutics, Inc. - Forward Price-to-Revenue Multiple|Forward Price to Sales TOVX|Gritstone Bio - Forward P/S Multiple|Market Cap to Expected Sales Ratio NexImmune Corporation NEXI|turnstonebio.com (TSBX) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue VCNX|HARP (Harpoon Therapeutics, Inc.) - Forward P/S Multiple